207
Participants
Start Date
September 6, 2021
Primary Completion Date
January 6, 2023
Study Completion Date
July 14, 2023
Semaglutide 2.4 mg
Administered subcutaneously (s.c., under the skin) once weekly as well as reduced-calorie diet and increased physical activity for 52 weeks. Doses gradually increased to 2.4 mg
Placebo
Administered subcutaneously once weekly (s.c., under the skin) as well as reduced-calorie diet and increased physical activity for 52 week
Hvidovre Hospital Endokrinologisk forsknings afsnit 159, Hvidovre
Aarhus Universitetshospital Diabetes og Hormonsygdomme, Aarhus N
Hospital Gregorio Marañón, Madrid
Hospital Clinico San Carlos, Madrid
StudyCor, Jyväskylä
Hospital Infanta Luisa, Seville
University of Calgary, Calgary
C-endo Diab Endo Clin Calgery, Calgary
Ocean West Research Clinic, Surrey
G.A. Research Associates Ltd., Moncton
LMC ClinRsrh Inc.Brampton, Brampton
LMC Clin Res Inc. Thornhill, Concord
Wharton Med Clin Trials, Hamilton
Premier Clinical Trial Research Network (PCTRN), Hamilton
Milestone Research, London
Toronto Sleep Institute/MedSleep, Toronto
Diabetes Heart Research Centre, Toronto
Centre Medical Acadie, Montreal
LMC Clin Rsrch Inc. (Montreal), Saint-Laurent
Centre de recherché du CHUS, Sherbrooke
Ctr de Med Metab de Lanaudiere, Terrebonne
Obesity Research Unit, Helsinki
Clifton Medical Centre, Rotherham
The Health Centre, Bradford-on-Avon
WISDEM Centre, Coventry
Claremont Medical Practice, Exmouth
GP Direct, Harrow
Guys Hospital, London
The Staploe Medical Centre, Soham
MyHealth - Strensall Health Care Centre, Strensall
Lead Sponsor
Novo Nordisk A/S
INDUSTRY